S-nitrosoglutathione acts as a small molecule modulator of human fibrin clot architecture

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Bateman, Ryon M ^a,b   Ellis, Christopher G ^c   Suematsu, Makoto ^a   Walley, Keith R ^b  

^a KEIO UNIVERSITY   (Japan)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

S NITROSOGLUTATHIONE; THROMBIN;

ARTICLE; CELL DENSITY; CELL MOTION; CELL SIZE; CELL STRUCTURE; COMPUTER PROGRAM; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FIBRIN CLOT; FIBRIN POLYMERIZATION; HUMAN; HUMAN CELL; IMAGE PROCESSING; MULTIPHOTON MICROSCOPY; QUANTITATIVE ANALYSIS; THROMBOCYTE POOR PLASMA;

FIBRIN; FIBRINOGEN; HUMANS; PLASMA; S-NITROSOGLUTATHIONE;

EID: 84865154948     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043660     Document Type: Article

References (50)

1. Collet JP, Allali Y, Lesty C, Tanguy ML, Silvain J, et al. ((2006)) Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol 26:: 2567--2573.
2. Mills JD, Ariens RA, Mansfield MW, Grant PJ, ((2002)) Altered fibrin clot structure in the healthy relatives of patients with premature coronary artery disease. Circulation 106:: 1938--1942.
3. Scott DJ, Prasad P, Philippou H, Rashid ST, Sohrabi S, et al. ((2011)) Clot architecture is altered in abdominal aortic aneurysms and correlates with aneurysm size. Arterioscler Thromb Vasc Biol 31:: 3004--3010.
4. Undas A, Podolec P, Zawilska K, Pieculewicz M, Jedlinski I, et al. ((2009)) Altered fibrin clot structure/function in patients with cryptogenic ischemic stroke. Stroke 40:: 1499--1501.
5. Vadseth C, Souza JM, Thomson L, Seagraves A, Nagaswami C, et al. ((2004)) Pro-thrombotic state induced by post-translational modification of fibrinogen by reactive nitrogen species. J Biol Chem 279:: 8820--8826.
6. Mosesson MW, DiOrio JP, Siebenlist KR, Wall JS, Hainfeld JF, ((1993)) Evidence for a second type of fibril branch point in fibrin polymer networks, the trimolecular junction. Blood 82:: 1517--1521.
7. Mosesson MW, Siebenlist KR, Amrani DL, DiOrio JP, ((1989)) Identification of covalently linked trimeric and tetrameric D domains in crosslinked fibrin. Proc Natl Acad Sci U S A 86:: 1113--1117.
8. Ryan EA, Mockros LF, Weisel JW, Lorand L, ((1999)) Structural origins of fibrin clot rheology. Biophys J 77:: 2813--2826.
9. Chernysh IN, Weisel JW, ((2008)) Dynamic imaging of fibrin network formation correlated with other measures of polymerization. Blood 111:: 4854--4861.
10. Ajjan R, Lim BC, Standeven KF, Harrand R, Dolling S, et al. ((2008)) Common variation in the C-terminal region of the fibrinogen beta-chain: effects on fibrin structure, fibrinolysis and clot rigidity. Blood 111:: 643--650.
11. Ariens RA, Philippou H, Nagaswami C, Weisel JW, Lane DA, et al. ((2000)) The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood 96:: 988--995.
12. Blomback B, Carlsson K, Hessel B, Liljeborg A, Procyk R, et al. ((1989)) Native fibrin gel networks observed by 3D microscopy, permeation and turbidity. Biochim Biophys Acta 997:: 96--110.
13. Carr ME, ((1988)) Fibrin formed in plasma is composed of fibers more massive than those formed from purified fibrinogen. Thromb Haemost 59:: 535--539.
14. Ferry JD, Morrison PR, ((1947)) Preparation and properties of serum and plasma proteins; the conversion of human fibrinogen to fibrin under various conditions. J Am Chem Soc 69:: 388--400.
15. Okada M, Blomback B, ((1983)) Calcium and fibrin gel structure. Thromb Res 29:: 269--280.
16. Parastatidis I, Thomson L, Burke A, Chernysh I, Nagaswami C, et al. ((2008)) Fibrinogen beta-chain tyrosine nitration is a prothrombotic risk factor. J Biol Chem 283:: 33846--33853.
17. Liu L, Yan Y, Zeng M, Zhang J, Hanes MA, et al. ((2004)) Essential roles of S-nitrosothiols in vascular homeostasis and endotoxic shock. Cell 116:: 617--628.
18. Stamler JS, Jaraki O, Osborne J, Simon DI, Keaney J, et al. ((1992)) Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. Proc Natl Acad Sci U S A 89:: 7674--7677.
19. Diesen DL, Hess DT, Stamler JS, ((2008)) Hypoxic vasodilation by red blood cells: evidence for an s-nitrosothiol-based signal. Circ Res 103:: 545--553.
20. Bramanti E, Angeli V, Mester Z, Pompella A, Paolicchi A, et al. ((2010)) Determination of S-nitrosoglutathione in plasma: comparison of two methods. Talanta 81:: 1295--1299.
21. Gaston B, Reilly J, Drazen JM, Fackler J, Ramdev P, et al. ((1993)) Endogenous nitrogen oxides and bronchodilator S-nitrosothiols in human airways. Proc Natl Acad Sci U S A 90:: 10957--10961.
22. Mendelsohn ME, O'Neill S, George D, Loscalzo J, ((1990)) Inhibition of fibrinogen binding to human platelets by S-nitroso-N-acetylcysteine. J Biol Chem 265:: 19028--19034.
23. Radomski MW, Rees DD, Dutra A, Moncada S, ((1992)) S-nitroso-glutathione inhibits platelet activation in vitro and in vivo. Br J Pharmacol 107:: 745--749.
24. Simon DI, Stamler JS, Jaraki O, Keaney JF, Osborne JA, et al. ((1993)) Antiplatelet properties of protein S-nitrosothiols derived from nitric oxide and endothelium-derived relaxing factor. Arterioscler Thromb 13:: 791--799.
25. Riba R, Nicolaou A, Troxler M, Homer-Vaniasinkam S, Naseem KM, ((2004)) Altered platelet reactivity in peripheral vascular disease complicated with elevated plasma homocysteine levels. Atherosclerosis 175:: 69--75.
26. Langford EJ, Brown AS, Wainwright RJ, de Belder AJ, Thomas MR, et al. ((1994)) Inhibition of platelet activity by S-nitrosoglutathione during coronary angioplasty. Lancet 344:: 1458--1460.
27. Langford EJ, Wainwright RJ, Martin JF, ((1996)) Platelet activation in acute myocardial infarction and unstable angina is inhibited by nitric oxide donors. Arterioscler Thromb Vasc Biol 16:: 51--55.
28. Sorragi CdL, Shishido SM, Lemos ME, Marcondes S, Antunes E, et al. ((2011)) In vitro evaluation of the safe margin, antithrombotic and antiproliferative actions for the treatment of restenosis: Nitric oxide donor and polymers. Cell Biochem Funct 29:: 207--214.
29. Akhter S, Vignini A, Wen Z, English A, Wang PG, et al. ((2002)) Evidence for S-nitrosothiol-dependent changes in fibrinogen that do not involve transnitrosation or thiolation. Proc Natl Acad Sci U S A 99:: 9172--9177.
30. Geer CB, Stasko NA, Rus IA, Lord ST, Schoenfisch MH, ((2008)) Influence of glutathione and its derivatives on fibrin polymerization. Biomacromolecules 9:: 1876--1882.
31. Catani MV, Bernassola F, Rossi A, Melino G, ((1998)) Inhibition of clotting factor XIII activity by nitric oxide. Biochem Biophys Res Commun 249:: 275--278.
32. Sakharov DV, Nagelkerke JF, Rijken DC, ((1996)) Rearrangements of the fibrin network and spatial distribution of fibrinolytic components during plasma clot lysis. Study with confocal microscopy. J Biol Chem 271:: 2133--2138.
33. Zipfel WR, Williams RM, Webb WW, ((2003)) Nonlinear magic: multiphoton microscopy in the biosciences. Nat Biotechnol 21:: 1369--1377.
34. Bateman RM, Hodgson KC, Kohli K, Knight D, Walley KR, ((2007)) Endotoxemia increases the clearance of mPEGylated 5000-MW quantum dots as revealed by multiphoton microvascular imaging. J Biomed Opt 12:: 064005.
35. Shah GA, Nair CH, Dhall DP, ((1987)) Comparison of fibrin networks in plasma and fibrinogen solution. Thromb Res 45:: 257--264.
36. Collet JP, Park D, Lesty C, Soria J, Soria C, et al. ((2000)) Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy. Arterioscler Thromb Vasc Biol 20:: 1354--1361.
37. Baradet TC, Haselgrove JC, Weisel JW, ((1995)) Three-dimensional reconstruction of fibrin clot networks from stereoscopic intermediate voltage electron microscope images and analysis of branching. Biophys J 68:: 1551--1560.
38. Marchi RC, Meyer MH, de Bosch NB, Arocha-Pinango CL, Weisel JW, ((2004)) A novel mutation (deletion of Aalpha-Asn 80) in an abnormal fibrinogen: fibrinogen Caracas VI. Consequences of disruption of the coiled coil for the polymerization of fibrin: peculiar clot structure and diminished stiffness of the clot. Blood Coagul Fibrinolysis 15:: 559--567.
39. Shacter E, Williams JA, Levine RL, ((1995)) Oxidative modification of fibrinogen inhibits thrombin-catalyzed clot formation. Free Radic Biol Med 18:: 815--821.
40. Pawloski JR, Hess DT, Stamler JS, ((2001)) Export by red blood cells of nitric oxide bioactivity. Nature 409:: 622--626.
41. Allen BW, Stamler JS, Piantadosi CA, ((2009)) Hemoglobin, nitric oxide and molecular mechanisms of hypoxic vasodilation. Trends Mol Med 15:: 452--460.
42. Gkaliagkousi E, Ritter J, Ferro A, ((2007)) Platelet-derived nitric oxide signaling and regulation. Circ Res 101:: 654--662.
43. Stamler JS, ((2004)) S-nitrosothiols in the blood: roles, amounts, and methods of analysis. Circ Res 94:: 414--417.
44. Hogg N, ((2000)) Biological chemistry and clinical potential of S-nitrosothiols. Free Radic Biol Med 28:: 1478--1486.
45. Vorp DA, Lee PC, Wang DH, Makaroun MS, Nemoto EM, et al. ((2001)) Association of intraluminal thrombus in abdominal aortic aneurysm with local hypoxia and wall weakening. J Vasc Surg 34:: 291--299.
46. Fontaine V, Jacob MP, Houard X, Rossignol P, Plissonnier D, et al. ((2002)) Involvement of the mural thrombus as a site of protease release and activation in human aortic aneurysms. Am J Pathol 161:: 1701--1710.
47. Gersh KC, Zaitsev S, Cines DB, Muzykantov V, Weisel JW, ((2011)) Flow-dependent channel formation in clots by an erythrocyte-bound fibrinolytic agent. Blood 117:: 4964--4967.
48. Cote HC, Lord ST, Pratt KP, ((1998)) gamma-Chain dysfibrinogenemias: molecular structure-function relationships of naturally occurring mutations in the gamma chain of human fibrinogen. Blood 92:: 2195--2212.
49. Weisel JW, ((2005)) Fibrinogen and fibrin. Adv Protein Chem 70:: 247--299.
50. Undas A, Ariens RA, ((2011)) Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler Thromb Vasc Biol 31:: e88--99.